In contrast, the SP142 assay uses the percentage of stained tumor-infiltrating immune cells (IC) to the tumor area to determine PD-L1-positive tumors for atezolizumab, with a cutoff value of 1% in IMpassion130. The gene discussed is CD274; the disease is neoplasm.